HomeCompareMKUL vs ABBV

MKUL vs ABBV: Dividend Comparison 2026

MKUL yields 3696.86% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MKUL wins by $3359133543993.37M in total portfolio value
10 years
MKUL
MKUL
● Live price
3696.86%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3359133543993.47M
Annual income
$3,189,419,904,659,486,700.00
Full MKUL calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MKUL vs ABBV

📍 MKUL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMKULABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MKUL + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MKUL pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MKUL
Annual income on $10K today (after 15% tax)
$314,232.90/yr
After 10yr DRIP, annual income (after tax)
$2,711,006,918,960,563,700.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MKUL beats the other by $2,711,006,918,960,542,700.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MKUL + ABBV for your $10,000?

MKUL: 50%ABBV: 50%
100% ABBV50/50100% MKUL
Portfolio after 10yr
$1679566771996.79M
Annual income
$1,594,709,952,329,755,600.00/yr
Blended yield
94.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MKUL
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-0.8
Piotroski
0/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MKUL buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMKULABBV
Forward yield3696.86%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$3359133543993.47M$102.3K
Annual income after 10y$3,189,419,904,659,486,700.00$24,771.77
Total dividends collected$3347517978690.71M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: MKUL vs ABBV ($10,000, DRIP)

YearMKUL PortfolioMKUL Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$380,386$369,685.77$11,550$430.00+$368.8KMKUL
2$13,549,368$13,142,355.52$13,472$627.96+$13.54MMKUL
3$452,004,035$437,506,211.16$15,906$926.08+$451.99MMKUL
4$14,123,937,638$13,640,293,320.21$19,071$1,382.55+$14123.92MMKUL
5$413,452,147,440$398,339,534,167.11$23,302$2,095.81+$413452.12MMKUL
6$11,340,200,341,285$10,897,806,543,524.30$29,150$3,237.93+$11340200.31MMKUL
7$291,485,375,324,008$279,351,360,958,833.72$37,536$5,121.41+$291485375.29MMKUL
8$7,022,515,682,323,467$6,710,626,330,726,778.00$50,079$8,338.38+$7022515682.27MMKUL
9$158,610,877,882,230,980$151,096,786,102,144,860.00$69,753$14,065.80+$158610877882.16MMKUL
10$3,359,133,543,993,474,000$3,189,419,904,659,486,700.00$102,337$24,771.77+$3359133543993.37MMKUL

MKUL vs ABBV: Complete Analysis 2026

MKULStock

Molekule Group, Inc., an interior space air purification technology company, provides air purification solutions for hospitals and other healthcare facilities. The company offers interior air sterilization and disinfection products for the eradication of harmful airborne pathogens, including COVID-19. Its air hygiene product, Purgo (pure-go), a medical device that provides continuous air filtration, sanitization, and supplemental ventilation solutions with technology applied in any indoor space, including in hospitals, offices, and elevators. The company's Purgo products feature SteriDuct, a proprietary germicidal technology that work to equipment and devices to reduce the exposure of occupants of interior spaces to airborne particles and pathogens; Air Mini+, a direct-to-consumer air purifier, which features include a particle sensor, five fan speeds, and automatic fan speed adjustment through the product's auto protect mode; Air Pro, a direct-to-consumer and business-to-business product for rooms of up to 1,000 square feet; and Air Pro Rx, a medical-grade purifier designed for traffic areas in healthcare facilities for rooms more than 600 square feet. It also offers PECO-HEPA Tri-Power filter; Molekule App, a mobile application that provides a 28 day look back of IAQ trends sensed by the Air Pro air purifier, breaking down pollutants detected, including VOCs, and pollutants that range from PM 1 to PM 10 in size; and Molekule Air Platform, a dashboard that allows data from multiple air purifiers and controls to be accessed in one interface. The company was formerly known as AeroClean Technologies, Inc. and changed its name to Molekule Group, Inc. in January 2023. Molekule Group, Inc. was founded in 2011 and is headquartered in Palm Beach Gardens, Florida.

Full MKUL Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MKUL vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MKUL vs SCHDMKUL vs JEPIMKUL vs OMKUL vs KOMKUL vs MAINMKUL vs JNJMKUL vs MRKMKUL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.